Table 1 Baseline characteristics
Characteristic | Tirzepatide (n = 364) | Placebo (n = 367) |
|---|---|---|
Age (years) | 65.5 ± 10.5 | 65.0 ± 10.9 |
Women | 200 (54.9%) | 193 (52.6%) |
Race | ||
American Indian, Alaska Native or Pacific Islanders | 26 (7.1%) | 24 (6.5%) |
Asian | 58 (15.9%) | 73 (19.9) |
Black or African American | 22 (6.0%) | 14 (3.8%) |
White | 256 (70.3%) | 256 (69.8%) |
Other or mixed race | 2 (0.5%) | 0 (0.0%) |
Ethnicity | ||
Hispanic or Latino | 195 (53.6%) | 205 (55.9%) |
Not Hispanic or Latino | 164 (45.1%) | 159 (43.3%) |
Region | ||
United States | 83 (22.8%) | 68 (18.5%) |
Latin America | 193 (53.0%) | 197 (53.7%) |
Asia | 58 (15.9%) | 73 (19.9%) |
Other | 30 (8.2%) | 29 (7.9%) |
Measures of adiposity | ||
Body weight (kg) | 102.9 ± 21.7 | 103.1 ± 22.7 |
BMI (kg m−2) | 38.3 ± 6.4 | 38.2 ± 7.0 |
Waist circumference (cm) | 120 ± 15 | 120 ± 14 |
HFpEF severity and phenotyping | ||
NYHA Class II | 262 (72.0%) | 268 (73.0%) |
NYHA Class III–IV | 102 (28.0%) | 99 (27.0%) |
NT-proBNP, median (IQR), ng l−1 | 196 (56, 488) | 169 (64, 476) |
KCCQ-CSS score | 53.9 ± 17.9 | 53.2 ± 19.0 |
6MWD (m) | 305.0 ± 80.0 | 300.6 ± 83.5 |
Left ventricular ejection fraction (%) | 61.0 ± 6.5 | 60.6 ± 6.2 |
High-sensitivity troponin T, median (IQR), (ng l−1) | 11 (7–19) | 12 (8–19) |
Elevated troponin T (>14 ng l−1), n (%) | 151 (42.2%) | 147 (40.6%) |
Current atrial fibrillation, n (%) | 95 (26.1%) | 91 (24.8%) |
Cardiovascular history | ||
Hospitalization for HF within 12 months | 171 (47.0%) | 172 (46.9%) |
Diabetes mellitus | 174 (47.8%) | 178 (48.5%) |
Coronary artery disease | 111 (30.9%) | 106 (29.1%) |
Cardiovascular medications | ||
Diuretics | 267 (73.4%) | 271 (73.8%) |
RAS and neprilysin inhibitors | 293 (80.5%) | 295 (80.4%) |
Beta blocker | 245 (67.3%) | 263 (71.7%) |
Mineralocorticoid receptor antagonist | 131 (36.0%) | 125 (34.1%) |
Sodium–glucose cotransporter 2 inhibitor | 69 (19.0%) | 57 (15.5%) |
